

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rhodes Jason P</u>  (Last) (First) (Middle) C/O DYNE THERAPEUTICS, INC. 830 WINTER ST.  (Street) WALTHAM MA 02451  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics, Inc. [ DYN ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/26/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/26/2024		S <sup>(1)</sup>		136,312	D	\$23.59 <sup>(2)</sup>	6,216,250	I	See footnote <sup>(3)</sup>
Common Stock	02/26/2024		S <sup>(1)</sup>		64,783	D	\$23.98 <sup>(4)</sup>	6,151,467	I	See footnote <sup>(3)</sup>
Common Stock	02/26/2024		S <sup>(5)</sup>		20,205	D	\$23.59 <sup>(2)</sup>	1,564,932	I	See footnote <sup>(6)</sup>
Common Stock	02/26/2024		S <sup>(5)</sup>		9,603	D	\$23.98 <sup>(4)</sup>	1,555,329	I	See footnote <sup>(6)</sup>
Common Stock	02/26/2024		S <sup>(7)</sup>		11,736	D	\$23.59 <sup>(2)</sup>	909,107	I	See footnote <sup>(8)</sup>
Common Stock	02/26/2024		S <sup>(7)</sup>		5,580	D	\$23.98 <sup>(4)</sup>	903,527	I	See footnote <sup>(8)</sup>
Common Stock	02/27/2024		S <sup>(1)</sup>		272,923	D	\$24.38 <sup>(9)</sup>	5,878,544	I	See footnote <sup>(3)</sup>
Common Stock	02/27/2024		S <sup>(1)</sup>		25,779	D	\$24.68 <sup>(10)</sup>	5,852,765	I	See footnote <sup>(3)</sup>
Common Stock	02/27/2024		S <sup>(5)</sup>		40,455	D	\$24.38 <sup>(9)</sup>	1,514,874	I	See footnote <sup>(6)</sup>
Common Stock	02/27/2024		S <sup>(5)</sup>		3,821	D	\$24.68 <sup>(10)</sup>	1,511,053	I	See footnote <sup>(6)</sup>
Common Stock	02/27/2024		S <sup>(7)</sup>		23,505	D	\$24.38 <sup>(9)</sup>	880,022	I	See footnote <sup>(8)</sup>
Common Stock	02/27/2024		S <sup>(7)</sup>		2,216	D	\$24.68 <sup>(10)</sup>	877,806	I	See footnote <sup>(8)</sup>
Common Stock	02/28/2024		S <sup>(1)</sup>		152,244	D	\$24.83 <sup>(11)</sup>	5,700,521	I	See footnote <sup>(3)</sup>
Common Stock	02/28/2024		S <sup>(1)</sup>		2,430	D	\$25.25 <sup>(12)</sup>	5,698,091	I	See footnote <sup>(3)</sup>
Common Stock	02/28/2024		S <sup>(5)</sup>		22,567	D	\$24.83 <sup>(11)</sup>	1,488,486	I	See footnote <sup>(6)</sup>
Common Stock	02/28/2024		S <sup>(5)</sup>		360	D	\$25.25 <sup>(12)</sup>	1,488,126	I	See footnote <sup>(6)</sup>
Common Stock	02/28/2024		S <sup>(7)</sup>		13,109	D	\$24.83 <sup>(11)</sup>	864,697	I	See footnote <sup>(8)</sup>
Common Stock	02/28/2024		S <sup>(7)</sup>		210	D	\$25.25 <sup>(12)</sup>	864,487	I	See footnote <sup>(8)</sup>

